
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Breast Cancer Core Needle Biopsy Market**

According to Intelli, the U.S. Breast Cancer Core Needle Biopsy Market size was valued at USD 380.56 Million in 2024 and is projected to reach USD 530.29 Million by 2032, growing at a CAGR of 4.76% from 2025 to 2032.



Breast cancer core needle biopsy is a critical diagnostic procedure used to accurately identify the presence of cancerous cells in breast tissue. This minimally invasive technique involves extracting small cylinders, or "cores," of tissue from a suspicious area in the breast using a hollow needle, typically guided by imaging technologies such as ultrasound, mammography, or MRI. Unlike fine needle aspiration (FNA), which involves using a thin needle to withdraw fluid or small clusters of cells, core needle biopsy (CNB) goes a step further by obtaining larger, solid tissue samples that preserve the architecture of the tissue. This distinction is crucial because the structure and arrangement of cells within the tissue provide valuable context that cannot be seen in the more limited samples collected via FNA. With CNB, pathologists are able to perform a comprehensive histological examination, which includes identifying whether the tumor is malignant or benign, determining the exact type of breast cancer (such as ductal or lobular carcinoma), and assessing its grade, an indication of how aggressive or fast-growing the tumor may be. In addition, core needle biopsy allows for immunohistochemical testing to assess key biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These receptors play a crucial role in guiding treatment decisions, as their presence or absence helps determine the most appropriate therapeutic approach. For instance, tumors that are ER or PR positive are more likely to respond to hormone-based therapies, while HER2-positive cancers may be effectively treated with targeted drugs like trastuzumab. By providing this detailed molecular information, CNB supports the development of personalized treatment plans tailored to each patient’s specific cancer profile. Its importance lies in its ability to provide a definitive diagnosis without the need for surgical intervention, reducing patient discomfort, recovery time, and healthcare costs, while ensuring timely and precise treatment decisions that can significantly improve outcomes.

**U.S. Breast Cancer Core Needle Biopsy Market Definition**

A close-up of hands holding a tablet and a pen

Description automatically generated**​**The U.S. breast cancer core needle biopsy market is a significant segment within the broader diagnostic landscape, characterized by its role in facilitating minimally invasive, accurate tissue sampling for breast cancer diagnosis. This market comprises a diverse array of advanced technologies designed to enhance diagnostic accuracy and patient comfort. These include ultrasound-guided biopsies, which are widely used due to their real-time imaging and ease of access, MRI-guided biopsies, ideal for detecting abnormalities not visible on other imaging modalities, and stereotactic-guided biopsies, which use mammographic images to precisely locate and target suspicious lesions. Each method offers unique advantages based on the clinical context, enabling clinicians to select the most appropriate approach for accurate tissue sampling.

**U.S. Breast Cancer Core Needle Biopsy Market Overview**

The U.S. breast cancer core needle biopsy market is driven by several key factors that collectively contribute to its steady growth and advancement. One of the most significant drivers is the high and growing prevalence of breast cancer among women. Breast cancer remains the most commonly diagnosed cancer in women in the United States, with hundreds of thousands of new cases reported annually. This alarming incidence rate increases the need for efficient and reliable diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. Early diagnosis is critical for improving survival rates, reducing the severity of treatment required, and enhancing overall patient outcomes. Alongside this, growing awareness about the importance of routine breast cancer screening has led to increased adoption of image-guided biopsy techniques. Moreover, the growth of the U.S. breast cancer core needle biopsy market is strongly supported by ongoing technological advancements in biopsy devices. Innovations such as vacuum-assisted core needle systems, automated biopsy guns, and real-time imaging integration (using ultrasound, MRI, or stereotactic guidance) have significantly improved the accuracy, speed, and safety of the biopsy process. These advancements not only enhance diagnostic precision but also minimize patient discomfort and reduce the likelihood of repeat procedures. At the same time, favorable reimbursement frameworks from private insurers and government programs like Medicare and Medicaid ensure that more patients have access to these advanced diagnostic services without facing financial barriers. Lastly, the increasing focus on personalized medicine, which relies on detailed A close-up of hands holding a tablet and a pen

Description automatically generatedmolecular and histopathological information provided by CNB, continues to boost its demand, positioning it as an essential tool in modern breast cancer management.

**U.S. Breast Cancer Core Needle Biopsy Market Segmentation**

The U.S. breast cancer core needle biopsy market is segmented based on several key factors, which help define the structure and dynamics of the industry.

**U.S. Breast Cancer Core Needle Biopsy Market, By Type of Biopsy Technique**

* **Ultrasound-Guided Core Needle Biopsy**
* **MRI-Guided Core Needle Biopsy**
* **Stereotactic-Guided Core Needle Biopsy**

The U.S. breast cancer core needle biopsy market is primarily driven by three key biopsy techniques, ultrasound-guided, MRI-guided, and stereotactic-guided core needle biopsies, each contributing distinct advantages based on the nature of the tumor and the imaging requirements. Among these, ultrasound-guided core needle biopsy holds the largest market share, accounting for a significant portion of the procedures due to its cost-effectiveness, real-time imaging, and widespread availability in clinical settings. Stereotactic-guided core needle biopsy, though less commonly used than ultrasound, is highly effective in detecting microcalcifications and non-palpable lesions visible on mammograms. MRI-guided core needle biopsy, although more specialized and expensive, is gaining traction due to its exceptional sensitivity in detecting abnormalities not visible on traditional imaging, especially in high-risk patients or those with dense breast tissue.

**U.S. Breast Cancer Core Needle Biopsy Market, By Product**

* **Needle-Based Biopsy Guns**
* **Vacuum-Assisted Biopsy Devices**

In the U.S. breast cancer core needle biopsy market, two primary product categories dominate, needle-based biopsy guns and vacuum-assisted biopsy devices, each catering to distinct clinical needs. Needle-based biopsy guns hold the largest market share due to their affordability, ease of use, and efficiency in providing accurate tissue samples with minimal invasiveness. In contrast, vacuum-assisted biopsy devices are steadily increasing their market share, particularly in more complex cases where precise and comprehensive tissue sampling is crucial. These devices stand out by enabling the collection of larger tissue samples with fewer needle insertions, which not only enhances the accuracy of the A close-up of hands holding a tablet and a pen

Description automatically generateddiagnosis but also reduces the need for multiple procedures. This ability to obtain high-quality samples in a single pass significantly improves diagnostic yield, ensuring that pathologists can make more informed decisions. As the demand for precision and patient-centered care grows, both product categories continue to evolve, with vacuum-assisted biopsy devices seeing a steady rise in adoption due to their superior sampling capabilities.

**U.S. Breast Cancer Core Needle Biopsy Market, By End User**

* **Hospitals**
* **Diagnostic & Imaging Centers**
* **Ambulatory Surgical Centers**
* **Academic & Research Institutes**

The U.S. breast cancer core needle biopsy market is characterized by its diverse end users, each contributing to the broad adoption of this diagnostic procedure across various healthcare settings. Hospitals are the largest end users, given their comprehensive medical infrastructure, specialized equipment, and skilled healthcare professionals. Diagnostic and imaging centers are also key players in the market, providing specialized outpatient services that prioritize early detection and routine screenings. These centers often enable faster, more cost-effective biopsies, ensuring that patients can access timely and efficient diagnostic procedures without the need for lengthy hospital stays. Ambulatory surgical centers are gaining traction due to their efficiency in performing minimally invasive procedures, offering patients a less expensive alternative with shorter recovery times compared to hospital settings. Finally, academic and research institutes play a pivotal role in advancing breast cancer diagnostics through clinical trials and innovative research, contributing to the development of new biopsy technologies and techniques.

**Key Players**

The “U.S. breast cancer core needle biopsy market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Hologic, Inc., Boston Scientific, Medtronic, Becton Dickinson and Company, Johnson & Johnson, Intact Vascular, Stryker Corporation, Cook Medical, Siemens Healthineers, GE Healthcare, Thermo Fisher Scientific, SPECTRA MEDICAL DEVICES, LLC, Ethicon Surgical Technologies, Guardant Health, Inc, Merit Medical Systems, among others. Our market analysis also entails a A close-up of hands holding a tablet and a pen

Description automatically generatedsection solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, Researchers have developed an advanced deep learning algorithm designed to analyze BI-RADS 4 suspicious lesions on mammograms. This algorithm aims to differentiate between malignant and benign lesions more accurately, ultimately helping to reduce the number of unnecessary biopsies.
* In 2024, the development of an ultrasensitive liquid biopsy, that can detect signs of breast cancer recurrence up to three years before it shows up on traditional imaging, is a notable advancement.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. breast cancer core needle biopsy market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. breast cancer core needle biopsy market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. BREAST CANCER CORE NEEDLE BIOPSY MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. BREAST CANCER CORE NEEDLE BIOPSY MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. BREAST CANCER CORE NEEDLE BIOPSY MARKET, BY TYPE OF BIOPSY TECHNIQUE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Ultrasound-Guided Core Needle Biopsy

5.3 MRI-Guided Core Needle Biopsy

5.4 Stereotactic-Guided Core Needle Biopsy

**6 U.S. BREAST CANCER CORE NEEDLE BIOPSY MARKET, BY PRODUCT**

6.1 Overview

6.2 Needle-Based Biopsy Guns

6.3 Vacuum-Assisted Biopsy Devices

**7 U.S. BREAST CANCER CORE NEEDLE BIOPSY MARKET, BY END-USER**

7.1 Overview

7.2 Hospitals

7.3 Diagnostic & Imaging Centers

7.4 Ambulatory Surgical Centers

7.5 Academic & Research Institutes

1. **U.S. BREAST CANCER CORE NEEDLE BIOPSY MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 Hologic, Inc.**

* + 1. Overview
    2. A close-up of hands holding a tablet and a pen

       Description automatically generatedFinancial Performance
    3. roduct Outlook
    4. Key developments
  1. **Boston Scientific**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Medtronic**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Becton Dickinson and Company**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Intact Vascular**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  6. **Stryker Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Cook Medical**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Siemens Healthineers**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **GE Healthcare**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Thermo Fisher Scientific**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  4. **SPECTRA MEDICAL DEVICES, LLC**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Ethicon Surgical Technologies**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Guardant Health, Inc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Merit Medical Systems**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. A close-up of hands holding a tablet and a pen

      Description automatically generated Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research